Indo-MIM: strong numbers, but FY26 raises important questions
A newly listed company where the core is now the thing to track. Revenue grew 26%, but more than half the increment came from a loosely defined segment nobody has broken out.
| Metric | Value |
|---|---|
| FY26 revenue +25.9% YoY | ₹4,193 crore |
| FY26 EBITDA +14.8%; margin 25.5%, down ~247bps | ₹1,071 crore |
| FY26 PAT +26%, helped by ₹128 crore of other income | ₹534 crore |
| Return on capital employed up from 23.5% in FY25 | 26.6% |
| Operating cash flow against ₹506 crore in FY25 | ₹1,077 crore |
| Capex against PAT of ₹534 crore | ₹417 crore |
| Repeat customers largest customer only 8%; 1,100+ customers | 91.6% of revenue |
| Export share down from ~90% as domestic revenue nearly tripled | 77% |
| Product types manufactured across 15 facilities in India, US, UK and Mexico | 9,000+ |
Indo-MIM listed on 30 July 2026 and has already risen 7% at the time of writing. So it now becomes interesting to read this company and keep tracking the key elements that may make or break the story.
The model in short
Indo-MIM manufactures small, complex and highly precise metal components that go inside larger products such as cars, surgical instruments, aircraft systems, firearms, mobile phones and industrial equipment.
The customer designs the final product while Indo-MIM manufactures the tiny metal components inside it. The difficult part is not making one component — the complexity lies in manufacturing millions of identical components while maintaining the exact same dimensions, strength and quality every single time. That is where Indo-MIM has built its expertise.
For example, a medical-device company may need a cartridge base for a surgical stapler. It gives Indo-MIM the required design and specifications. Indo-MIM develops the mould, manufactures samples, gets the part approved and then supplies lakhs of identical components. The customer pays for every finished component supplied.
So Indo-MIM is not selling machines or raw metal. It is selling a custom-made, ready-to-use metal component. The company manufactured more than 9,000 product types in FY26 and operates 15 manufacturing facilities across India, the US, the UK and Mexico.
What is MIM, and why is it useful?
Indo-MIM originally built its business around Metal Injection Moulding, or MIM. In simple terms, MIM allows a company to manufacture small and complicated metal parts using a mould.
Without MIM, the component may have to be cut out of a metal block through several machining steps. That can be costly and wasteful when millions of small parts are required. Once the mould is ready, Indo-MIM can manufacture the same complicated component repeatedly and at scale.
MIM remains the main business, but Indo-MIM has also added casting, machining, ceramic components, metal 3D printing, powder manufacturing, finishing and assembly. It is no longer only a MIM manufacturer — it is becoming a broader precision metal-component manufacturing company.
According to the Frost & Sullivan report commissioned by Indo-MIM, the company had an estimated 6.8% share of the global MIM market and FY26 MIM revenue of approximately ₹2,454 crore, around 58.5% of total revenue. These are estimates from a company-commissioned industry report, not independently audited market-share figures.
Why customers stay for years
Before mass production starts, Indo-MIM must develop a mould specifically for the component, manufacture samples, pass the customer's tests and factory inspections, and prove that every piece meets the required quality. This process can take two to three years.
Once approved, changing the supplier is difficult. The customer may have to develop a new mould, repeat testing and approve the component all over again. That creates switching costs and makes customer relationships sticky.
This is visible in the numbers: repeat customers generated 91.6% of FY26 revenue; the largest customer contributed only 8%; the top ten contributed 38.4%; and Indo-MIM served more than 1,100 customers.
The company added 308 customers during FY26, but they contributed only 8.4% of revenue. New customers usually start small, while most revenue comes from older customers whose products have already entered mass production.
Revenue is diversified across industries
Indo-MIM generated ₹4,193 crore of revenue in FY26, up 26% YoY. These are the company's internal product-group abbreviations:
- APG — Automotive Products Group: components used in vehicle safety, fuel systems, powertrains and interiors.
- DPG — Defence Products Group: firearm components such as triggers, hammers and sights.
- MPG — Medical Products Group: components used in endoscopy, laparoscopy, dental robotics and orthopaedics.
- CPG — Consumer Products Group: components for mobile phones, tools, hardware and fashion accessories.
- Others — metal powder, tools and traded products.
| End-use industry | FY26 (₹ mn) | FY26 share | FY25 (₹ mn) | FY25 share | FY24 share |
|---|---|---|---|---|---|
| APG | 10,317.93 | 24.61% | 9,591.92 | 28.81% | 30.42% |
| CPG | 4,530.34 | 10.80% | 3,253.76 | 9.77% | 9.57% |
| DPG | 7,836.82 | 18.69% | 8,923.09 | 26.80% | 27.34% |
| MPG | 7,579.82 | 18.08% | 5,773.04 | 17.34% | 19.58% |
| Aerospace | 5,014.81 | 11.96% | 3,762.75 | 11.30% | 9.82% |
| Others | 6,650.13 | 15.86% | 1,991.21 | 5.98% | 3.27% |
| Total | 41,929.85 | 100.00% | 33,295.77 | 100.00% | 100.00% |
Notice one big thing: most of the FY26 revenue boost came from "Others", which grew more than 200%.
What exactly happened in "Others"?
Indo-MIM's overall revenue increased by ₹863 crore in FY26, or 26% YoY. Here is how each segment contributed to that net increase:
| Segment | Change in revenue | Contribution to total revenue growth |
|---|---|---|
| Others | +₹466 crore | 54.0% |
| Medical | +₹181 crore | 21.0% |
| Consumer | +₹128 crore | 14.8% |
| Aerospace | +₹125 crore | 14.5% |
| Automotive | +₹73 crore | 8.5% |
| Defence | −₹109 crore | −12.6% |
So around 54% of Indo-MIM's entire incremental FY26 revenue came from "Others". This category includes three very different types of revenue: metal powder, tooling, and traded products. These may not have similar margins or business quality.
Metal-powder manufacturing could be a strategically attractive backward-integration opportunity. Tooling revenue may indicate new customer programmes that later generate recurring component sales. Traded-product revenue, on the other hand, may involve lower manufacturing value addition and potentially lower margins.
The prospectus does not provide a separate revenue or profitability breakdown for these three activities.
Medical and aerospace are becoming more important
Medical revenue increased approximately 31% from ₹577 crore to ₹758 crore. Medical components generally have strict qualification requirements, long validation periods, significant quality requirements, and potentially long customer relationships. Indo-MIM's acquisition of Phoenix DeVentures also gives it medical-device design and development capabilities, which could allow it to enter earlier in the customer's product-development cycle rather than participating only at the manufacturing stage.
Aerospace revenue increased approximately 33% from ₹376 crore to ₹501 crore. Aerospace also has high qualification barriers and long product cycles. Once a component is approved for an aircraft platform or engine programme, the associated revenue can potentially remain sticky for several years.
Medical and aerospace together contributed approximately 30% of FY26 revenue, compared with around 29% in FY25 and 29% in FY24. The shares have not moved dramatically, but both are growing faster than automotive.
Defence weakened sharply
Defence revenue declined approximately 12% from ₹892 crore in FY25 to ₹784 crore in FY26. Its revenue share fell from 27.3% in FY24, to 26.8% in FY25, to 18.7% in FY26.
This is not merely a mix effect. Absolute defence revenue also declined.
The prospectus does not provide a detailed explanation for the fall. Defence orders can be programme-driven and uneven, so one year of weakness may not necessarily indicate a structural problem. But considering defence was previously one of Indo-MIM's largest segments, management needs to explain whether the decline was due to customer destocking, programme delays, demand weakness, shipment timing, customer-specific issues, or the loss of any programme.
A recovery in defence will be one of the most important things to monitor in next quarter's results.
The company remains export-oriented
Approximately 77% of FY26 revenue came from outside India, down from almost 90% in FY25. However, this does not mean export revenue declined. Overseas revenue increased from approximately ₹2,994 crore to ₹3,237 crore, growth of around 8%. The export share fell because domestic revenue almost tripled from ₹336 crore to ₹956 crore — and once again, most of the domestic increase came from "Others".
There is another interesting data point. Indo-MIM exported more than 250 million components in FY24, more than 300 million in FY25, but only more than 210 million in FY26. Export volumes declined substantially even though export revenue increased.
This could mean the company shifted towards fewer but higher-value components, which would be positive. But it could also mean weakness in certain high-volume programmes, partly offset by pricing, currency or product-mix benefits. So exports and their breakup become another key element to track.
The financial performance is strong
| KPI | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue from operations (₹ mn) | 41,929.85 | 33,295.77 | 28,703.95 |
| Revenue growth | 25.93% | 16.00% | 6.60% |
| EBITDA (₹ mn) | 10,709.23 | 9,325.97 | 7,434.62 |
| EBITDA margin | 25.54% | 28.01% | 25.90% |
| PAT (₹ mn) | 5,335.43 | 4,237.34 | 2,837.34 |
| PAT margin | 12.72% | 12.73% | 9.88% |
| Return on equity | 21.26% | 19.94% | 14.01% |
| Return on capital employed | 26.60% | 23.51% | 19.59% |
| Net debt to EBITDA | 0.65 | 1.15 | 1.15 |
Revenue compounded at approximately 21% between FY24 and FY26, while PAT compounded at approximately 37%. The absolute margin profile is excellent for a manufacturing business, and ROCE improving from 19.6% to 26.6% despite regular capital expenditure is another positive sign.
But FY26 did not produce operating leverage
FY25 was an excellent operating-leverage year: revenue grew 16%, while EBITDA grew 25% and PAT grew 49%. EBITDA margin expanded from 25.9% to 28%.
FY26 was different. Revenue grew 25.9%, but EBITDA grew only 14.8%. EBITDA margin declined by approximately 247 basis points to 25.5%. The major expense movements help explain this — particularly higher cost of goods and employee expenses.
It does not mean Indo-MIM's margins are weak. A 25.5% EBITDA margin remains excellent. But the key question has changed from "can this company earn strong margins?" to "can it sustain those margins while growing outside its core MIM business?"
PAT growth was supported by other income
Indo-MIM's PAT increased approximately 26% to ₹534 crore. However, other income increased from ₹44 crore to ₹128 crore, primarily driven by approximately ₹80 crore of net foreign-exchange gains and approximately ₹37 crore of compensation received from customers following contract cancellations.
Customer compensation and currency gains should not be treated as core recurring operating income. At the same time, finance costs increased from approximately ₹96 crore to ₹167 crore. So PAT grew strongly, but the path was not entirely clean.
Cash flow was strong
Cash flow from operations increased sharply to approximately ₹1,077 crore in FY26, compared with ₹506 crore in FY25. Cash expenditure on property, plant, equipment and intangible assets was approximately ₹417 crore — a strong number compared with PAT of ₹534 crore.
However, FY26 cash flow received support from a reduction in other current and non-current assets, favourable movements in financial liabilities, and the add-back of non-cash impairment charges. So ₹1,077 crore should not automatically be considered the recurring annual cash-flow base.
The underlying working-capital movements were still encouraging. Inventory was broadly flat at approximately ₹895 crore despite revenue growing 26%. Trade receivables increased approximately 19%, slower than revenue growth of 26%, indicating collections broadly kept pace.
So the company is cash-flow positive and free-cash-flow positive. Inventory is nothing to worry about and receivables show timely payments.
Capex plans
Indo-MIM is establishing an iron-powder manufacturing facility in Karnataka, targeted for completion by the end of FY27. The company already manufactures stainless-steel powder. Iron-powder manufacturing could reduce dependence on external suppliers, improve supply security, expand material options and possibly increase internal value addition. But the project's capital requirement, expected revenue and expected return on capital have not been disclosed.
An under-construction facility in Tamil Nadu is intended to house a new tool-room and machining unit. The company had also deployed 436 robots and 476 IoT-enabled machines by March 2026, and intends to keep investing in automation, productivity and capacity utilisation.
The direction is positive, but upcoming quarters should demonstrate that new capacity generates revenue and returns rather than simply increasing depreciation and fixed costs.
Capital allocation is the biggest non-operating concern
Indo-MIM's core manufacturing business appears strong, but its overseas acquisition record has been less successful.
The company acquired Triax in the US and CMG Technologies in the UK to add new manufacturing capabilities and expand its geographical presence. However, both businesses subsequently performed below the expectations used at the time of acquisition. As a result, Indo-MIM has repeatedly reduced their value in its accounts through impairment charges.
An impairment does not mean fresh cash was lost during that particular year — the cash was spent when the business was originally acquired. It means the company now believes the acquired business is worth less than previously estimated.
Phoenix DeVentures, its latest US acquisition, is therefore important to track. Its medical-device design capabilities could help win more medical business, but investors should watch whether it produces meaningful revenue, profits and cash flow. Any further overseas acquisition should be examined carefully — particularly the purchase price, profitability of the target and the returns Indo-MIM expects to generate.
What I want to see next
Indo-MIM has already proved that it can grow profitably. The key now is understanding the quality and sustainability of that growth.
| What | Why it matters |
|---|---|
| Growth from the core business | FY26 revenue grew strongly, but more than half the incremental revenue came from the loosely defined "Others" segment. I would like to see growth increasingly driven by core precision-component businesses |
| More clarity on "Others" | Management needs to explain how much comes from metal powder, tooling and traded products — and whether the segment earns margins comparable to the core |
| Operating leverage returning | Revenue grew faster than EBITDA in FY26 and margins fell from 28.0% to 25.5%. As utilisation improves, EBITDA growth should once again outpace revenue |
| Margin recovery through better mix | Operating leverage alone may not be enough. Improvement should also come from complex, value-added products in medical, aerospace and other high-precision applications |
| Clarity on capex and revenue conversion | How much capex is maintenance versus growth, when new capacity becomes operational, and how much revenue and return on capital it can generate |
| Export growth and domestic mix | A falling export share is not necessarily negative if domestic revenue grows faster at healthy margins. Focus on absolute export growth, volumes, realisations and the profitability of domestic growth |
| Better performance from acquisitions | Triax and CMG have already required impairments. Phoenix DeVentures must demonstrate it can generate revenue, profits, cash and additional medical opportunities |
13 min read